



# sotatercept powder and solvent for solution for injection (Winrevair®)

Merck Sharp & Dohme (UK) Limited

7 August 2026

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation:

**sotatercept (Winrevair®)** is not recommended for use within NHSScotland.

**Indication under review:** in combination with other pulmonary arterial hypertension (PAH) therapies for the treatment of PAH in adult patients with WHO Functional Class (FC) IV.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

SMC has previously accepted **sotatercept (Winrevair®)** for restricted use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity (SMC2923). This advice remains valid.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

Chair  
Scottish Medicines Consortium